E0 ConsensusModerate confidencePEM unclearReview-NarrativePeer-reviewedMachine draft
The neuroendocrinology of chronic fatigue syndrome and fibromyalgia.
Parker, A J, Wessely, S, Cleare, A J · Psychological medicine · 2001 · DOI
Quick Summary
This review examined how hormones and brain chemicals differ in ME/CFS patients. Researchers found that some patients have lower stress hormone (cortisol) levels, and their bodies show unusual patterns in serotonin and other brain chemical systems when tested. However, the findings were inconsistent across studies, and it's still unclear whether these changes cause ME/CFS symptoms or result from living with the illness.
Why It Matters
This systematic review consolidates evidence that ME/CFS involves measurable biological changes in hormone and neurotransmitter systems, supporting the view that the condition has physiological mechanisms. Understanding these neuroendocrine patterns may help guide future research and validate patients' experiences of fatigue and other symptoms.
Observed Findings
- Approximately one-third of studies found significantly low baseline cortisol levels, typically affecting one-third of patients studied.
- Neuroendocrine challenge tests showed more consistent evidence of reduced HPA axis function across studies.
- Enhanced serotonin (5-HT) function was demonstrated on neuroendocrine challenge testing.
- Abnormalities in the opioid system and arginine vasopressin (AVP) were identified in some patients.
- The growth hormone axis appeared to remain intact in CFS patients.
Inferred Conclusions
- Disturbance of the HPA axis is likely important in ME/CFS pathophysiology, but the mechanism involves complex interactions between cortisol and central neurotransmitter function rather than low cortisol alone.
- Methodological differences between studies may explain inconsistent findings regarding baseline cortisol levels.
- Longitudinal studies of at-risk populations are needed to determine whether neuroendocrine changes precede, accompany, or follow symptom onset.
Remaining Questions
- How do neuroendocrine abnormalities mechanistically relate to the experience of fatigue and other ME/CFS symptoms?
- Are observed hormonal and neurotransmitter changes primary drivers of ME/CFS or secondary responses to behavioral changes (sleep disruption, activity limitation)?
What This Study Does Not Prove
This review does not establish whether neuroendocrine abnormalities are the primary cause of ME/CFS or secondary consequences of the illness. It also does not clarify how specific hormonal or neurotransmitter changes translate into experienced symptoms, nor does it prove causation—only that associations exist.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:PEM Not DefinedWeak Case Definition
Metadata
- DOI
- 10.1017/s0033291701004664
- PMID
- 11722149
- Review status
- Machine draft
- Evidence level
- Established evidence from major reviews, guidelines, or evidence maps
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →